Single dose dexamethasone prophylaxis of postembolisation syndrome after chemoembolisation in hepatocellular carcinoma patient: A randomised, double-blind, placebo-controlled study

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 30

Peer-Review Report of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Clin Cases. Oct 26, 2021; 9(30): 9059-9069
Published online Oct 26, 2021. doi: 10.12998/wjcc.v9.i30.9059

Full Size Figure Download Figure

Figure 3 The incidences of common terminology criteria for adverse events.

Citation: Sainamthip P, Kongphanich C, Prasongsook N, Chirapongsathorn S. Single dose dexamethasone prophylaxis of postembolisation syndrome after chemoembolisation in hepatocellular carcinoma patient: A randomised, double-blind, placebo-controlled study. World J Clin Cases 2021; 9(30): 9059-9069
URL: https://www.wjgnet.com/2307-8960/full/v9/i30/9059.htm
DOI: https://dx.doi.org/10.12998/wjcc.v9.i30.9059

Sainamthip P, Kongphanich C, Prasongsook N, Chirapongsathorn S. Single dose dexamethasone prophylaxis of postembolisation syndrome after chemoembolisation in hepatocellular carcinoma patient: A randomised, double-blind, placebo-controlled study. World J Clin Cases 2021; 9(30): 9059-9069 [PMID: 34786388 DOI: 10.12998/wjcc.v9.i30.9059]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.